Product
Belamaf
Aliases
Belantamab mafodotin, GSK2857916 BLENREP
Name
Belamaf
Target
B-cell maturation antigen
FDA Approved
No
Ema approved
Status
0
1 clinical trial
2 drugs
1 abstract
1 indication
5 posters
Indication
Multiple MyelomaDrug
BelamafClinical trial
A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple MyelomaStatus: Recruiting, Estimated PCD: 2027-09-29
Poster
Synergistic Activity of Belantamab Mafodotin with Nirogacestat in BCMA-Expressing Cancer Cell LinesAbstract
A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM‑3.Org: Clinica São Germano, São Paulo, Brazil, General Hospital Evangelismos, Athens, Greece, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary, Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil, GSK, Upper Providence, PA,